Genetics News & Analysis | Business 2.0
- Illumina vs Guardant vs Natera: The MRD Market Landscape 2026
- The Quiet Genetics Infrastructure Shift Illumina and CRISPR Therapeutics
- Genetics in 2026: Illumina and CRISPR Therapeutics Expose a Widening
- Top Genetics Investment Priorities for 2026, According to Illumina, Thermo Fisher and Roche
- Why Healthcare Is Accelerating Genetics in 2026, Led by Roche and Illumina
- Why Genetics Is Becoming Core to Enterprise Strategy in 2026, According to Roche, Illumina and Deloitte
- Top 10 Genetics Startups to Watch in 2026
- Why Enterprises Are Scaling Genetics Platforms in 2026, According to Roche, Illumina and Thermo Fisher
- Global Genetics Outlook 2026: Enterprise Adoption Accelerates
- Emerging Genetics Technologies That Will Dominate 2026
- Genentech Boosts Holly Springs Investment to $2 Billion for Job Growth
- How Machine Learning Transforms Stem Cell Imaging and Analysis for Laboratories
- KKR And Carlyle Target Genetics Assets As 23andMe And SOPHiA Weigh Offers
- Invitae Winds Down Operations and Cuts Staff as Genetics Restructuring Widens
- EU Gene-Editing Deal and New FDA Guidance Rewire Genetics Playbook, Pricing and Access
- Genetics Players Push Cross-Border Deals: Oxford Nanopore, Illumina Target Asia and Middle East Expansion
- Genetics Market Trends: Country Comparisons Shaping 2025
- Genetics Statistics: Sequencing Scales, Clinical Uptake, and the $100 Genome Race
- Genetics by the Numbers: Costs Fall as Clinical Use Accelerates
- Genetics Innovation Hits an Inflection Point as Editing Moves From Lab to Market